Shares of SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, tumbled on Thursday after the announcement of the pricing of a share offering of 12 million shares and accompanying warrants at $0.75 per share, to raise $9 million.
Currently, SELLAS's stock is falling 35.4%, to $0.5850 on a volume of 2,350,522 from its previous close of $0.9055. It has traded between $0.5801 and $4.13 in the past 52-week period.
The accompanying warrants will expire in five years after its issuance.
The offering will close on or about January 8, 2024, the company said in a statement.
A.G.P./Alliance Global Partners acts as sole placement agent for this offering.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.